Naproxcinod clinical study results presented at the 2009 World Congress on Osteoarthritis

NicOx S.A. (NYSE Euronext Paris: COX) today announced that it has made three scientific presentations at the 2009 World Congress on Osteoarthritis (annual congress of the Osteoarthritis Research Society International - OARSI), which was held from September 10 to 13 in Montreal, Canada. The presentations included the following data:

- Efficacy results from the 302 study for naproxcinod, which was completed in 2008 (see NicOx press release dated September 15, 2008), were presented in a poster entitled '302 study: A Randomized, Parallel Group, Double- Blind, Placebo and Naproxen Controlled, Multicenter Phase 3 Study of Naproxcinod in Subjects with Osteoarthritis of the Knee: Efficacy Results Following 13-Week Treatment' (poster number 320). Naproxcinod is NicOx' lead compound and the first-in-class Cyclooxygenase-Inhibiting Nitric Oxide- Donating (CINOD) anti‑inflammatory agent.

- Preclinical results obtained with two other CINOD compounds were presented in two posters entitled 'Anti‑Inflammatory Effects and Gastrointestinal Safety of the Cyclooxygenase-Inhibiting Nitric Oxide Donator (CINOD) HCT 1026' (poster number 531) and 'Gastrointestinal Safety of the Cyclooxygenase-Inhibiting Nitric Oxide Donator (CINOD) HCT 2037 in a Rat Model of Inflammation' (poster number 532).